Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
Completed · Phase 1 · Has a placebo group
Conditions studied: Anthrax
In brief
Primary: • To compare the safety profile of a single intravenous administration of AVP-21D9 as compared with Placebo Secondary: * To evaluate the pharmacokinetics (PK) of a single intravenous administration of AVP-21D9 * To evaluate the immunogenicity of AVP-21D9
Key facts
- Study ID
- NCT01202695
- Run by
- Emergent BioSolutions
- People needed
- 50
- Starts
- 2010-08-01
- Expected to finish
- 2011-06-01
- Last updated by the study team
- 2024-03-15
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- ICON Development Solutions — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.